

7841-89

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

097402446

INTERNATIONAL APPLICATION NO.  
PCT/CA98/00325INTERNATIONAL FILING DATE  
7 April 1998PRIORITY DATE CLAIMED  
7 April 1997

## TITLE OF INVENTION

INTRAVENOUS IMMUNE GLOBULIN FORMULATION CONTAINING A NON-IONIC SURFACE  
ACTIVE AGENT WITH IMPROVED PHARMACOKINETIC PROPERTIES

## APPLICANT(S) FOR DO/EO/US

Hugh W. Price and B. Michael R. Woloski

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - (a) ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - (b) ☒ has been transmitted by the International Bureau.
  - (c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - (a) ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - (b) ☐ have been transmitted by the International Bureau.
  - (c) ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - (d) ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A **SUBSTITUTE SPECIFICATION**.
15. ☐ A **CHANGE OF POWER OF ATTORNEY AND/OR ADDRESS LETTER**.
16. ☐ Other items or information:



**BERESKIN & PARR**  
Box 401  
40 King Street West  
Toronto, Canada  
M5H 3Y2

Telephone (416) 364-7311  
Telecopier (416) 361-1398  
Internet BERESKIN&PARR.COM  
Cable ARNBEE Toronto

October 6, 1999

The Commissioner of Patents & Trademarks  
Washington, D.C., U.S.A. 20231

Dear Sir:

Transmitted herewith for entry into national phase of the patent application of

Inventors: Hugh W. Price and B. Michael R. Woloski


For: **INTRAVENOUS IMMUNE GLOBULIN FORMULATION CONTAINING A  
NON-IONIC SURFACE ACTIVE AGENT WITH IMPROVED  
PHARMACOKINETIC PROPERTIES**

The following papers are enclosed:

The following papers are enclosed:

- [X] Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) concerning a filing under 35 U.S.C. 371.
- [X] Preliminary Amendment.
- [X] An unsigned Combined Declaration for Patent Application and Power of Attorney.
- [X] The government filing fee in the amount of \$840.00 is included in our cheque No. \_\_\_\_\_. Please charge any deficiency or credit any overpayment to our deposit account No. 02-2095. A duplicate copy of this sheet is enclosed.
- [X] PAYMENT OF THE CLAIM FEES IS BEING DEFERRED.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 02-2095.
- [X] Convention priority is requested based on United States Provisional Application No. 60/041,921 filed on 7 April 1997.

Respectfully submitted,

  
\_\_\_\_\_  
Micheline Gravelle  
Registration No. 40,261